The National Comprehensive Cancer Network has released a follow-up survey on the ongoing chemotherapy shortages: 72% of the centers surveyed continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin.
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
